Contact Us

Fill out this form and we’ll respond as soon as we can.

Whether you’re interested in buying our products, distributing, or joining our team, we’d love to hear from you.

If you prefer, email us at cc@nowdx.com.

Corporate Headquarters
1200 Stewart Pl
Springdale, AR 72764

479.966.4535

Name *

Phone number *

Message (Maximum 2000 Characters)

Characters Remaining: 2000

Do you have a NOWDiagnostics account? *

Yes No

Check out what is making the news

Find out the latest in diagnostics testing.

FDA approves NOWDiagnostics’ ADEXUSDx® hCG Test

August 13, 2015

NOWDiagnostics, Inc. announced today that it has filed for expanded Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) of the ADEXUSDx® COVID-19 antibody test for point-of-care (POC)/CLIA waived testing. A prospective clinica...

American Pharmacists Association Foundation, NOWDiagnostics Launch Nationwide In-Pharmacy Real-Time COVID-19 Antibody Testing with Spike Protein-Targeted, Rapid ADEXUSDx® Test

July 19, 2021

The American Pharmacists Association Foundation (APhA Foundation) and NOWDiagnostics, Inc., a Springdale-based leader in innovative diagnostics testing, today announced that NOWDiagnostics’ ADEXUSDx® COVID-19 antibody test, a rapid-results self-contained fi...

BARDA and NOWDiagnostics Partner to Develop Rapid COVID-19 Antibody Test for Use Point-of-Care and At-Home

August 31, 2020

NOWDiagnostics, Inc. announced today it is working with BARDA, the Biomedical Advanced Research and Development Authority arm of the U.S. Department of Health and Human Services, to develop a serological test for SARS-CoV-2 antibodies that can be used acros...

NOWDiagnostics will provide tropical disease tests in Africa

March 16, 2017

Effective December 8, 2020, NOWDiagnostics, Inc. has received Conformité Européene (CE) mark approval for its ADEXUSDx® COVID-19 ‘antibody fingerstick’ Test for use across 28 countries in the European Union (EU). The test first received CE mark approval for use in moderate/complex laboratory settings on July 28, 2020. The application for fingerstick use of the test was submitted November 2020 following completion of a Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver trial in the United States (U.S.). C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics, will begin offering the ADEXUSDx® COVID-19 Test for fingerstick use in a variety of health care settings in the EU—from clinics to hospital emergency rooms, ...